Special Issue

Nanocarriers in Vaccine Applications

Message from the Guest Editors

The discovery of vaccines is by far the most important medical invention in recent centuries and has contributed to the eradication of many diseases. Nanotechnology has been highlighted as an important contributor in vaccine development for adjuvants and delivery systems. The combination of emerging nanotechnologies and subunit vaccines has led to the foundation of effective and safe vaccine development. In recent years, the effective use of lipid nanoparticle-based mRNA COVID-19 vaccines in clinical settings has underlined the potential of nanotechnology in vaccine development. Nanocarriers enhance the bioavailability of the vaccine and act as adjuvants to stimulate a higher immune response (humoral and cell-mediated immune responses), increasing the vaccination's efficacy. The Special Issue's aim is to highlight the development of new vaccines and vaccines that have been improved using novel nanocarrier formulations, with a focus on preclinical and clinical evaluation. This issue will also include articles that provide critical reviews of current advancements and updates on nanocarrier-based vaccines from experts in relevant fields.

Guest Editors

Dr. Robin Kumar
Dr. Jairam Meena
Dr. Ruchika Dehinwal

Deadline for manuscript submissions

closed (30 October 2023)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/136073

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI